Developer docs
API playgroundTry for free, no card

Search company profiles

Anacor Pharmaceutical

Full company profile

uuid0004oxu

Namestring
Anacor Pharmaceutical
Legal namestring
Pfizer Inc.
Websiteurl
anacor.com
Company typeenum
Public
Founded yearint
1849
Descriptiontext

Anacor Pharmaceutical is a biopharmaceutical company that developed small-molecule therapeutics derived from a proprietary boron chemistry platform. Founded in 2000 and headquartered in Palo Alto, California, the company leveraged the unique properties of the boron atom as a chemical scaffold for drug design, producing clinical-stage and commercial-stage assets targeting dermatological and infectious disease indications. Anacor's portfolio included tavaborole (Kerydin), an FDA-approved topical antifungal for onychomycosis, and crisaborole (Eucrisa), an FDA-approved topical treatment for mild-to-moderate atopic dermatitis that became a strategic asset in the dermatitis therapeutics market, which is projected to reach $8.94 billion globally by 2030 at a 5.0% CAGR.

The company's revenue model centered on prescription pharmaceutical sales of FDA-approved products distributed through pharmacy and healthcare provider channels, supplemented by milestone payments and royalties from strategic pharmaceutical partnerships. Capital formation included multiple venture rounds from 2002 through 2009 (with investors including Aberdare Ventures, Rho Ventures, Care Capital, Venrock, and Schering AG), strategic investments from GSK (2010), debt financing from Hercules Capital (2013), and a U.S. Department of the Treasury award (2010), with a final $250 million financing event in April 2016.

Anacor's operational scale was modest, with 51-100 employees and leadership including Paul L. Berns as Chief Executive Officer and President, Lucy Shapiro as Chairman and Co-Chair of the Scientific Advisory Board, Carmen R. Rodriguez as Senior Vice President of Regulatory Affairs and Quality, and James R. Marconi as Vice President of Finance and Controller. The company was listed on NASDAQ under ticker ANAC and is currently delisted, reflecting its acquisition by a strategic acquirer in 2016.

Short descriptiontext

Anacor Pharmaceutical was a Palo Alto-based biopharmaceutical company that developed small-molecule therapeutics from a proprietary boron chemistry platform, targeting dermatological and infectious diseases with FDA-approved products including Kerydin and Eucrisa.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPalo Alto, United States
HQ citystring
Palo Alto
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
small-molecule therapeutics, boron chemistry platform, dermatology pharmaceuticals, topical antifungal drugs, anti-inflammatory therapeutics
Industry2 codes
PRIMARYHLAIACAL
Dermatology Specialty Pharmaceuticals
SECONDARYEUAAAIAK
Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Medicinal and Botanical Manufacturing325411
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Dermatology Pharmaceuticals
Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Anacor Pharmaceutical is a biopharmaceutical company that develops small-molecule therapeutics derived from its proprietary boron chemistry platform, with a primary focus on dermatology indications including onychomycosis (toenail fungus) and atopic dermatitis. Its lead commercial product is tavaborole topical solution (Kerydin), an FDA-approved boron-based antifungal for onychomycosis, with the crisaborole program (later approved as Eucrisa) for atopic dermatitis representing a key pipeline asset.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Kerydin (tavaborole) Topical Solution, 5%
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Dermatology-focused biopharma commercializing topical roflumilast (Zoryve) for psoriasis and seborrheic dermatitis with an atopic dermatitis program in development. Directly comparable small-molecule, topical dermatology strategy mirroring Anacor's approach.

TypeEmerging player
Description

Clinical-stage dermatology company developing sofpironium bromide for primary axillary hyperhidrosis. Comparable as a smaller, dermatology-focused emerging player with a specialty small-molecule asset, similar in scale and stage to Anacor's pre-acquisition profile.

TypeDirect peer
Description

Emerging dermatology company developing topical therapeutics for atopic dermatitis and psoriasis, including the aryl hydrocarbon receptor agonist tapinarof (Vtama). Highly comparable to Anacor's crisaborole as a topical small-molecule entrant in the same indication space.

TypeEmerging player
Description

Develops and commercializes ruxolitinib cream (Opzelura) for atopic dermatitis and vitiligo — a topical JAK inhibitor directly competitive with Anacor's crisaborole in the mild-to-moderate atopic dermatitis segment.

TypeDirect peer
Description

Nestlé Health Science- and L'Oréal-backed pure-play dermatology company with prescription and consumer skincare products across acne, rosacea, eczema, and psoriasis. Directly comparable as a dermatology specialty pharma peer to Anacor's therapeutic focus, though at materially larger commercial scale.

TypeDirect peer
Description

Was a dermatology-focused biopharma developing lebrikizumab for atopic dermatitis before being acquired by Eli Lilly for ~$1.1B in 2020. Closely comparable to Anacor in therapeutic focus (atopic dermatitis) and in outcome (strategic acquisition by a large pharma).

TypeBroad incumbent
Description

Privately held Danish dermatology specialist with prescription products across psoriasis, eczema, and actinic keratosis. Comparable as a focused dermatology incumbent operating at much larger scale than Anacor.

TypeDirect peer
Description

Clinical-stage dermatology company developing small-molecule therapies for immuno-inflammatory skin diseases. Comparable to Anacor's specialty dermatology positioning, though with a broader JAK kinase focus rather than boron chemistry.

TypeBroad incumbent
Description

Anacor's acquirer; a top-tier global biopharma with an inflammation & immunology franchise that absorbed Anacor's platform and crisaborole. Relevant as the strategic counterparty that validates the platform and the most direct benchmark for value capture post-acquisition.

TypeBroad incumbent
Description

Large diversified specialty pharma with a meaningful dermatology franchise (Bausch + Lomb, Ortho Dermatologics) covering acne, psoriasis, and actinic keratosis. Comparable as a broad incumbent in dermatology pharma against Anacor's narrower specialty focus.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Anacor Pharmaceutical

Dermatology Pharmaceuticalsanacor.com

Anacor Pharmaceutical was a Palo Alto-based biopharmaceutical company that developed small-molecule therapeutics from a proprietary boron chemistry platform, targeting dermatological and infectious diseases with FDA-approved products including Kerydin and Eucrisa.

What Anacor Pharmaceutical does

Anacor Pharmaceutical is a biopharmaceutical company that developed small-molecule therapeutics derived from a proprietary boron chemistry platform. Founded in 2000 and headquartered in Palo Alto, California, the company leveraged the unique properties of the boron atom as a chemical scaffold for drug design, producing clinical-stage and commercial-stage assets targeting dermatological and infectious disease indications. Anacor's portfolio included tavaborole (Kerydin), an FDA-approved topical antifungal for onychomycosis, and crisaborole (Eucrisa), an FDA-approved topical treatment for mild-to-moderate atopic dermatitis that became a strategic asset in the dermatitis therapeutics market, which is projected to reach $8.94 billion globally by 2030 at a 5.0% CAGR.

The company's revenue model centered on prescription pharmaceutical sales of FDA-approved products distributed through pharmacy and healthcare provider channels, supplemented by milestone payments and royalties from strategic pharmaceutical partnerships. Capital formation included multiple venture rounds from 2002 through 2009 (with investors including Aberdare Ventures, Rho Ventures, Care Capital, Venrock, and Schering AG), strategic investments from GSK (2010), debt financing from Hercules Capital (2013), and a U.S. Department of the Treasury award (2010), with a final $250 million financing event in April 2016.

Anacor's operational scale was modest, with 51-100 employees and leadership including Paul L. Berns as Chief Executive Officer and President, Lucy Shapiro as Chairman and Co-Chair of the Scientific Advisory Board, Carmen R. Rodriguez as Senior Vice President of Regulatory Affairs and Quality, and James R. Marconi as Vice President of Finance and Controller. The company was listed on NASDAQ under ticker ANAC and is currently delisted, reflecting its acquisition by a strategic acquirer in 2016.

Anacor Pharmaceutical firmographics

Firmographics
Name
Anacor Pharmaceutical
Legal name
Pfizer Inc.
Website
https://anacor.com
Company type
Public
Founded year
1849
Operating status
Operating
Headcount range
11–50 employees
Short description
Anacor Pharmaceutical was a Palo Alto-based biopharmaceutical company that developed small-molecule therapeutics from a proprietary boron chemistry platform, targeting dermatological and infectious diseases with FDA-approved products including Kerydin and Eucrisa.
Ownership category
akta.pro rank

Anacor Pharmaceutical industry classification

Industry
Product category
Dermatology Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIACAL
Dermatology Specialty Pharmaceuticals
SECONDARYEUAAAIAK
Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)

Keywords

  • Small-molecule therapeutics
  • Boron chemistry platform
  • Dermatology pharmaceuticals
  • Topical antifungal drugs
  • Anti-inflammatory therapeutics

Where Anacor Pharmaceutical is headquartered

Location

Headquarters

HQ city
Palo Alto
HQ country
United States
HQ region
North America

Markets served

Anacor Pharmaceutical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Distribution channels1 record

Anacor Pharmaceutical product offering

Product offering

Core offering

Anacor Pharmaceutical is a biopharmaceutical company that develops small-molecule therapeutics derived from its proprietary boron chemistry platform, with a primary focus on dermatology indications including onychomycosis (toenail fungus) and atopic dermatitis. Its lead commercial product is tavaborole topical solution (Kerydin), an FDA-approved boron-based antifungal for onychomycosis, with the crisaborole program (later approved as Eucrisa) for atopic dermatitis representing a key pipeline asset.

Differentiator

Problem solved

Functional benefit

Products and services

  • Kerydin (tavaborole) Topical Solution, 5%

Companies that use Anacor Pharmaceutical

Customer profile

Ideal customer profiles1 record

Anacor Pharmaceutical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Anacor Pharmaceutical partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves6 records

Expansion highlights3 records

Anacor Pharmaceutical competitors and assessment

Company assessment

Direct peers

  • Arcutis Biotherapeutics: Dermatology-focused biopharma commercializing topical roflumilast (Zoryve) for psoriasis and seborrheic dermatitis with an atopic dermatitis program in development. Directly comparable small-molecule, topical dermatology strategy mirroring Anacor's approach.
  • Dermavant Sciences: Emerging dermatology company developing topical therapeutics for atopic dermatitis and psoriasis, including the aryl hydrocarbon receptor agonist tapinarof (Vtama). Highly comparable to Anacor's crisaborole as a topical small-molecule entrant in the same indication space.
  • Galderma: Nestlé Health Science- and L'Oréal-backed pure-play dermatology company with prescription and consumer skincare products across acne, rosacea, eczema, and psoriasis. Directly comparable as a dermatology specialty pharma peer to Anacor's therapeutic focus, though at materially larger commercial scale.
  • Dermira: Was a dermatology-focused biopharma developing lebrikizumab for atopic dermatitis before being acquired by Eli Lilly for ~$1.1B in 2020. Closely comparable to Anacor in therapeutic focus (atopic dermatitis) and in outcome (strategic acquisition by a large pharma).
  • Aclaris Therapeutics: Clinical-stage dermatology company developing small-molecule therapies for immuno-inflammatory skin diseases. Comparable to Anacor's specialty dermatology positioning, though with a broader JAK kinase focus rather than boron chemistry.

Emerging players

  • Brickell Biotech: Clinical-stage dermatology company developing sofpironium bromide for primary axillary hyperhidrosis. Comparable as a smaller, dermatology-focused emerging player with a specialty small-molecule asset, similar in scale and stage to Anacor's pre-acquisition profile.
  • Incyte Corporation: Develops and commercializes ruxolitinib cream (Opzelura) for atopic dermatitis and vitiligo — a topical JAK inhibitor directly competitive with Anacor's crisaborole in the mild-to-moderate atopic dermatitis segment.

Broad incumbents

  • LEO Pharma: Privately held Danish dermatology specialist with prescription products across psoriasis, eczema, and actinic keratosis. Comparable as a focused dermatology incumbent operating at much larger scale than Anacor.
  • Pfizer: Anacor's acquirer; a top-tier global biopharma with an inflammation & immunology franchise that absorbed Anacor's platform and crisaborole. Relevant as the strategic counterparty that validates the platform and the most direct benchmark for value capture post-acquisition.
  • Bausch Health (formerly Valeant Pharmaceuticals): Large diversified specialty pharma with a meaningful dermatology franchise (Bausch + Lomb, Ortho Dermatologics) covering acne, psoriasis, and actinic keratosis. Comparable as a broad incumbent in dermatology pharma against Anacor's narrower specialty focus.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Anacor Pharmaceutical social profiles

Digital presence

Anacor Pharmaceutical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Anacor Pharmaceutical leadership team

Management profile

Number of profiles

Profiles4 records

Anacor Pharmaceutical funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Anacor Pharmaceutical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Anacor Pharmaceutical

What does Anacor Pharmaceutical do?

Anacor Pharmaceutical is a biopharmaceutical company that develops small-molecule therapeutics derived from its proprietary boron chemistry platform, with a primary focus on dermatology indications including onychomycosis (toenail fungus) and atopic dermatitis. Its lead commercial product is tavaborole topical solution (Kerydin), an FDA-approved boron-based antifungal for onychomycosis, with the crisaborole program (later approved as Eucrisa) for atopic dermatitis representing a key pipeline asset.

Is Anacor Pharmaceutical a public or private company?

Anacor Pharmaceutical is a public company. It is classified as corporate owned and is currently operating.

When was Anacor Pharmaceutical founded?

Anacor Pharmaceutical was founded in 1849. It employs 11 to 50 people.

Where is Anacor Pharmaceutical based?

Anacor Pharmaceutical is headquartered in Palo Alto, United States, in the North America region.

Who are Anacor Pharmaceutical's main competitors?

Direct peers on record are Arcutis Biotherapeutics, Dermavant Sciences, Galderma, Dermira and Aclaris Therapeutics. Emerging players are Brickell Biotech and Incyte Corporation. Broad incumbents are LEO Pharma, Pfizer and Bausch Health (formerly Valeant Pharmaceuticals).

Does Anacor Pharmaceutical have an API?

No public API is recorded for Anacor Pharmaceutical.

What industry is Anacor Pharmaceutical in?

Anacor Pharmaceutical's product category is Dermatology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAL, Dermatology Specialty Pharmaceuticals, with a secondary code of EUAAAIAK, Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswirePerrigo Confirms Patent Challenge For Generic Version Of Kerydin®Anacor Pharmaceuticals, Inc. initiated patent litigation on October 25, 2018 in the U.S. District Court for the District of Delaware against Perrigo Company plc regarding Perrigo's Paragraph IV Abbreviated New Drug Application for tavaborole topical solution, 5%, a generic version of the antifungal treatment Kerydin\u00ae. The litigation, filed under the Hatch-Waxman Act, challenges Perrigo's attempt to market the generic while patents for Kerydin\u00ae remain in effect, with the drug generating $77 million in annual sales as of August 2018. Perrigo stated the filing demonstrates its ongoing efforts to develop extended topical generic products that reduce healthcare costs.PR NewswireSuneva Medical Expands their Prestigious Board of Directors with the Appointment of Vince IppolitoSuneva Medical, Inc. has appointed Vince Ippolito to its Board of Directors, citing his extensive experience in the pharmaceuticals and aesthetic medicine industries. Ippolito previously served as Chief Commercial Officer at Anacor Pharmaceuticals and Medicis, bringing significant expertise in marketing, sales, and product portfolio strategy. This addition aims to leverage his industry knowledge to support Suneva's growth and strategic direction.PR NewswireGlobal Market Study on Dermatophytic Onychomycosis Therapeutics (DOT): North America Expected to Account for Maximum Market Share by 2021, Due to Increasing Prevalence of Fungal Toe Nail InfectionsReportlinker published a global market study on dermatophytic onychomycosis therapeutics, projecting that North America held the dominant market share at over 43% in 2014, while the nail paint segment is expected to account for maximum market share by 2021 with an 8.3% CAGR. The Asia Pacific region is forecast to expand at the highest CAGR of 5.1% during the 2015-2021 period. Key players identified in the market include Valeant Pharmaceuticals International Inc., Galderma S.A., Novartis AG, Pfizer Inc., Moberg Pharma AB, Johnson & Johnson Services, Inc., and Anacor Pharmaceuticals, Inc.PR NewswireGlobal Medicated Skin Care Products - Consumer HealthcareThis report provides a comprehensive analysis of the worldwide medicated skin care products market, covering annual estimates and forecasts for the period 2015 through 2022 across major geographic regions including the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World markets. The report identifies key growth drivers such as increasing prevalence of skin diseases, aging population demographics, rising demand for anti-aging products, and expanding wellness trends, while profiling 120 companies including major players such as Pfizer, Nestlé Skin Health, Galderma, Unilever, and Bayer. Notable recent industry activities documented include Pfizer's acquisition of Anacor Pharmaceuticals, Cadila's acquisition of the Melgain brand from Issar Pharma, and multiple FDA approvals for new medicated skin care formulations.PR NewswireFDA approves Eucrisa for eczemaThe U.S. Food and Drug Administration approved Eucrisa (crisaborole) ointment on December 14, 2016, for treating mild to moderate eczema (atopic dermatitis) in patients two years of age and older. The drug, a phosphodiesterase 4 (PDE-4) inhibitor manufactured by Anacor Pharmaceuticals, demonstrated efficacy in two placebo-controlled trials with 1,522 participants, with users achieving greater response with clear or almost clear skin after 28 days of treatment.Financial ExpressHow Wellcome and Gates charities profit from helping biotechWellcome Trust will profit from U.S. FDA approval of Axumin, a cancer test developed by its biotech arm Syncona. The Gates Foundation made an $80 million profit from selling a stake in Anacor Pharmaceuticals to Pfizer. Both charities use investments to fund charitable work.PR NewswireAre These Biotech Stocks Prescribed for Investors' Portfolio? - Anacor Pharma, Athersys, Aralez Pharma and Infinity PharmaActiveWallSt.com featured four biotech stocks—Anacor Pharmaceuticals, Athersys, Aralez Pharmaceuticals, and Infinity Pharmaceuticals—in a sponsored report analyzing their recent market performance. The article provides specific trading data for each company, including stock prices, volume, and technical indicators like the Relative Strength Index. It includes disclaimers that the content is sponsored and not intended as investment advice.PR NewswireSHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Anacor Pharmaceuticals, Inc. -ANACBrodsky & Smith, LLC announced an investigation of Anacor Pharmaceuticals' board over possible breaches of fiduciary duty in the Pfizer sale. Anacor shareholders receive $99.25 per share, while stock traded at $152.25 on August 4, 2015, and an analyst set a $130 price target.PR NewswireSHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Anacor Pharmaceuticals, Inc. -ANACLaw firm Brodsky & Smith, LLC announced an investigation into the Board of Directors of Anacor Pharmaceuticals, Inc. for potential breaches of fiduciary duty in connection with the company's sale to Pfizer, Inc. The transaction offers Anacor shareholders $99.25 per share in cash, significantly below the company's $152.25 share price from August 2015 and an analyst price target of $130.00 per share. The investigation will examine whether the sale undervalues Anacor and would result in substantial losses for shareholders.PR NewswireRyan & Maniskas, LLP Announces Investigation of Anacor Pharmaceuticals, Inc.Ryan & Maniskas, LLP has launched an investigation into potential breaches of fiduciary duty by the board of directors of Anacor Pharmaceuticals regarding its proposed sale to Pfizer Inc. for approximately $5.2 billion. Under the agreement, Anacor shareholders are set to receive $99.25 in cash per share.